nuclear transport factor 2 pseudogene 5Genealiases: []
Q-omics provides the consensus-scored NUTF2P5 profile across patient tissues and cancer cell-line models. NUTF2P5 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, NUTF2P5 is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, NUTF2P5 RNA expression shows 8,458 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight BLCA, LUSC, and GBM as cancer lineages where NUTF2P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NUTF2P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NUTF2P5 survival associations across molecular data types. NUTF2P5 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NUTF2P5 RNA expression–survival associations across cancer types. High NUTF2P5 expression shows unfavorable associations in BLCA, READ, CESC and SKCM, but favorable associations in LUAD and ESCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for NUTF2P5 RNA expression.
This table summarizes NUTF2P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for NUTF2P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NUTF2P5 shows lower tumor expression in LUSC. The LUSC box plot shows higher NUTF2P5 RNA expression in normal versus tumor tissue (log2 FC = −0.083, t-test p = .032).
This table shows molecular features associated with NUTF2P5 in patient tissues and cancer cell lines. In patient samples, NUTF2P5 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
